Granules India gains after USFDA completes surveillance inspection at Jeedimetla facility with zero observations

23 Jun 2023 Evaluate

Granules India is currently trading at Rs. 288.75, up by 1.20 points or 0.42% from its previous closing of Rs. 287.55 on the BSE.

The scrip opened at Rs. 287.55 and has touched a high and low of Rs. 290.50 and Rs. 281.40 respectively. So far 56630 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 238.05 on 23-Jun-2022.

Last one week high and low of the scrip stood at Rs. 297.50 and Rs. 281.40 respectively. The current market cap of the company is Rs. 6928.47 crore.

The promoters holding in the company stood at 42.02%, while Institutions and Non-Institutions held 28.93% and 29.05% respectively.

US Food & Drug Administration (USFDA) has successfully completed surveillance inspection at Granules India’s Jeedimetla facility located at Hyderabad, Telangana, India from June 19, 2023 to June 23, 2023 with zero (0) 483 observations. Jeedimetla facility manufactures Active Pharmaceutical Ingredients (API) and Pharmaceutical Formulation Intermediates (PFIs).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).


Granules India Share Price

585.50 -7.40 (-1.25%)
27-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1861.70
Dr. Reddys Lab 1389.35
Cipla 1506.15
Lupin 2228.00
Zydus Lifesciences 972.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.